Home » Topics » BioWorld Science

BioWorld Science
RSS

Saniona to study Tesomet in phase IIa trial for hypothalamic obesity

June 11, 2018

First-in-human study evaluates AZD-4205 with osimertinib in advanced NSCLC

June 11, 2018

MaxCyte and NIH enter CRADA for sickle cell disease

June 11, 2018

Responses to M-7824 in phase I study lead to phase II trial in HPV-associated cancers

June 11, 2018

Tagrisso approved in E.U. for first-line EGFR-mutated NSCLC

June 11, 2018

Evgen offers interim update from phase II STEM trial of SFX-01 in advanced breast cancer

June 11, 2018

EBX-205, a new oral broad-spectrum antibiotic active against bioterrorism pathogens

June 11, 2018

Idorsia initiates phase II registration program for nemorexant in insomnia

June 11, 2018

FDA approves Venclexta plus rituximab for previously treated CLL and SLL

June 11, 2018

Rapalimus gel launched in Japan for the treatment of angiofibromas in tuberous sclerosis

June 11, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...